Safety and efficacy of exercise training in adults with Pompe disease: Evalution of endurance, muscle strength and core stability before and after a 12 week training program

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Van Den Berg, Linda E M ^a   Favejee, Marein M ^a,b   Wens, Stephan C A ^b   Kruijshaar, Michelle E ^a   Praet, Stephan F E ^b   Reuser, Arnold J J ^b   Bussmann, Johannes B J ^b   Van Doorn, Pieter A ^b   Van Der Ploeg, Ans T ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Core stability; Endurance training; Glycogen storage disorder type II; Muscle function; Strength training

Indexed keywords

CREATINE KINASE;

ABDUCTION; ABSENCE OF COMPLICATIONS; ADULT; AEROBIC EXERCISE; AGED; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORE STABILITY; CREATINE KINASE BLOOD LEVEL; ENDURANCE TRAINING; ENZYME REPLACEMENT; FEASIBILITY STUDY; FEMALE; FLEXOR MUSCLE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; MALE; MUSCLE EXERCISE; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCULOSKELETAL SYSTEM PARAMETERS; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; PATIENT SAFETY; TREATMENT DURATION; TREATMENT RESPONSE; WALKING DISTANCE; WORKLOAD; ENDURANCE; GLYCOGEN STORAGE DISEASE TYPE II; KINESIOTHERAPY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGRAM EVALUATION; YOUNG ADULT;

ADULT; AGED; ENZYME REPLACEMENT THERAPY; EXERCISE THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; PHYSICAL ENDURANCE; PROGRAM EVALUATION; YOUNG ADULT;

EID: 84937563100     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0303-0     Document Type: Article

References (31)

1. Engel AG, Hirschhorn R, Huie MI. Acid maltase deficiency. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 2004. p. 1559-86.
2. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet.2008;372(9646):1342-53.
3. Engel AG. Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain. 1970;93(3):599-616.
4. Laforet P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 2000;55(8):1122-8.
5. van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.
6. de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.
7. Gungor D, Kruijshaar ME, Plug I, D'Agostino RB, Hagemans ML, van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.
8. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013;260(4):951-9.
9. Slonim AE, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2007;35(1):70-7.
10. Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol. 2010;257(1):91-7.
11. Favejee MM, Huisstede BM, Bussmann JB, Kruijshaar ME, van der Ploeg AT. Physiotherapy management in late-onset Pompe disease: clinical practice in 88 patients. Mol Genet Metab. 2012;107(1-2):111-5.
12. Clarkson PM, Hubal MJ. Exercise-induced muscle damage in humans. Am J Phys Med Rehabil. 2002;81(11 Suppl):S52-69.
13. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2(2):92-8.
14. Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ. Measurements during integrative cardiopulmonary exercise testing. In: Weinberg R, editor. Principles of exercise testing. Baltimore: Lippincott, Williams and Wilkins; 1999. p. 62-94.
15. Parkhouse KL, Ball N. Influence of dynamic versus static core exercises on performance in field based fitness tests. J Bodyw Mov Ther. 2011;15(4):517-24.
16. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186-97.
17. van Capelle CI, van der Beek NA, de Vries JM, van Doorn PA, Duivenvoorden HJ, Leshner RT, et al. The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis. 2012;35(2):317-23.
18. van den Berg LE, Zandbergen AA, van Capelle CI, de Vries JM, Hop WC, van den Hout JM, et al. Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. Bone. 2010;47(3):643-9.
19. Lo MS, Lin LL, Yao WJ, Ma MC. Training and detraining effects of the resistance vs. endurance program on body composition, body size, and physical performance in young men. J Strength Cond Res. 2011;25(8):2246-54.
20. Quinlivan R, Vissing J, Hilton-Jones D, Buckley J. Physical training for McArdle disease. Cochrane Database Syst Rev. 2011;12, CD007931.
21. Shephard RJ. Intensity, duration and frequency of exercise as determinants of the response to a training regime. Int Z Angew Physiol. 1968;26(3):272-8.
22. Sveen ML, Jeppesen TD, Hauerslev S, Kober L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain. 2008;131(Pt 11):2824-31.
23. Crescimanno G, Modica R, Lo Mauro R, Musumeci O, Toscano A, Marrone O. Role of the cardio-pulmonary exercise test and six-minute walking test in the evaluation of exercise performance in patients with late-onset Pompe disease. Neuromuscul Disord. 2015;25(7):542-7.
24. Marzorati M, Porcelli S, Reggiori B, Morandi L, Grassi B. Improved exercise tolerance after enzyme replacement therapy in Pompe disease. Med Sci Sports Exerc. 2012;44(5):771-5.
25. Goemans N, Klingels K, van den Hauwe M, Van Orshoven A, Vanpraet S, Feys H, et al. Test-retest reliability and developmental evolution of the 6-min walk test in Caucasian boys aged 5-12 years. Neuromuscul Disord. 2013;23(1):19-24.
26. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve. 2010;42(6):966-74.
27. Nilsson MI, Samjoo IA, Hettinga BP, Koeberl DD, Zhang H, Hawke TJ, et al. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab. 2012;107(3):469-79.
28. Terzis G, Krase A, Papadimas G, Papadopoulos C, Kavouras SA, Manta P. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2012;107(4):669-73.
29. Case LE, Kishnani PS. Physical therapy management of Pompe disease. Genet Med. 2006;8(5):318-27.
30. Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267-88.
31. Fowler Jr WM. Role of physical activity and exercise training in neuromuscular diseases. Am J Phys Med Rehabil. 2002;81(11 Suppl):S187-95.